Dry and Wet Age-Related Macular Degeneration | TreatmentTrends | US | 2014
TreatmentTrends: Dry/Wet Age-Related Macular Degeneration (US) is an annual syndicated report series that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and competitive landscape through comprehensive primary research with U.S. retinal specialists and general ophthalmologists. The report covers the current use of intravitreal injections, in particular anti-VEGF agents, for the treatment of AMD, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth, promotional activity, and anticipated use. In addition, respondents are queried about their awareness of and inter-est in products in development.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
